ANN ARBOR, Michigan, April 18, 2018 /PRNewswire/ -- Swift Biosciences today announced the commercial release of its Accel-Amplicon Plus™ Cancer NGS Panels, a suite of nine tumor-specific and focused gene panels to facilitate targeted cancer sequencing. The Accel-Amplicon technology enables simultaneous detection of single nucleotide variants, copy number variants and small insertion and deletions to achieve comprehensive and exon-level hotspot coverage of clinically-relevant genes. It also allows researchers to combine pre-validated content and their own targets into a fast, single-tube assay to develop more informative and scalable workflows to better achieve their scientific goals.
Every tumor harbors a unique combination of genomic alterations, which may determine tumor growth rate and response to treatment. Targeted sequencing using focused, multigene panels provides a precise and informative method to quickly identify clinically actionable variants within known or putative cancer genes. However, developing cancer gene panels requires bioinformatics expertise to identify genetic markers and additional resources to design, optimize and validate an assay.
Accel-Amplicon Plus provides a modular, mix-and-match capability that gives translational laboratories greater flexibility to deploy more than one strategy. Laboratories may either begin with a broad gene set to comprehensively profile tumors and then refine the content to the most informative markers, or start with a very focused assay to routinely screen known, clinically actionable variants. Each assay can be designed to accommodate up to 1500 amplicons per panel, are designed and wet-lab validated by Swift's experts, and are fully compatible with degraded FFPE or diluted liquid biopsy samples.
"Accel-Amplicon Plus Cancer Panels could revolutionize cancer and oncology research," said Haley Fiske, Chief Commercial Office at Swift Biosciences. "By integrating pre-validated and customizable content into a single panel, clinical researchers can maximize data generated from every tumor sample and accelerate their efforts to discover and screen cancer variants."
The Accel-Amplicon Plus Cancer Panels consist of nine assays:
Key features and benefits of the Accel-Amplicon Plus Cancer NGS Panels include:
With highly informative content, an easy protocol and reliable results, the panels enable several critical oncology applications, including:
In parallel with the Accel-Amplicon Plus Cancer Panel release, the company launched the Swift Bioinformatics Resources, an offering of open source and commercial solutions to expedite analysis of large NGS data sets. The first two tools support Swift's targeted resequencing workflow, including Primerclip™, an open source tool for primer trimming, and FAST Analysis™, an intuitive variant detection software from Genialis that seamlessly integrates alignment, allele calling and summary report.
The Accel-Amplicon Plus Cancer NGS Panels are commercially available now. Visit www.swiftbiosci.com to learn more.
About Swift Biosciences
Swift Biosciences is the NGS Library Prep company. Based in Ann Arbor, Michigan, the company develops novel library preparation solutions for emerging applications based on next-generation sequencing, including whole genome sequencing, targeted DNA sequencing, and epigenetic analysis.
Swift Biosciences' products are designed to help customers analyze challenging biological samples faster, easier, and with greater sensitivity and accuracy, while being compatible with leading instrumentation. Swift Biosciences is the first company to offer library preparation solutions on all three major sequencing platforms, including Pacific Biosciences®, Illumina® and Ion Torrent™.
The company opened its doors in February 2010, and its product development enables new applications in multiple industries, including agrigenomics, pharmaceutical, academic, biotechnology, and oncology research fields.
For more information, visit SwiftBioSci.com and follow Swift Biosciences on Twitter (@SwiftBioSci).
CONTACT: Darby Wagner , Lambert, Edwards & Associates, (616) 258-5779, firstname.lastname@example.org